Impaired sleep-wakefulness and quality of life in patients with arterial hypertension and chronic kidney disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. determination of the effect of impaired sleep-wakefulness on quality of life (QoL) indicators in patients suffering from arterial hypertension (ah) and chronic kidney disease (ckd). material and methods. 55 patients including 20 (36.4%) men and 35 (63.6%) women with documented arterial hypertension and ckd were randomized in the study. to assess the sleep quality (SQ), the Pittsburgh qs index (PSQi); the Athens insomnia scale (Ais) were used; qol was assessed using the sf-36 questionnaire. results. most of the study participants showed a decrease in sq and an impaired sleep-wakefulness. this leads to a decrease in qol in patients with arterial hypertension and ckd. Impaired sleep-wakefulness in patients of this group most pronouncedly affect such criteria for assessing quality of life as physical functioning, pain intensity, mental health, and especially life activity. Conclusion. Violation of the sleep quality was inherent in the majority of the examined. Impaired sleep-wakefulness leads to a decrease in qol in patients suffering from arterial hypertension and ckd.

Full Text

Restricted Access

About the authors

E. V Osipov

Rostov State Medical University

Email: aaaw2001@mail.ru
Candidate of Medical Sciences, Assistant of the Department of Internal Diseases №2 Rostov-on-Don, Russia

M. M Batyushin

Rostov State Medical University

Email: batjushin-m@rambler.ru
Doctor of Medicine, Professor of the Department of internal diseases №2 Rostov-on-Don, Russia

Z. M Nalgieva

Rostov State Medical University

Email: zmnalgieva@gmail.com
resident of the Department of Internal Diseases №2 Rostov-on-Don, Russia

References

  1. Olsen M.H., Angell S.Y., Asma S., et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016;388:2665- 712. https://doi.org/10.1016/S0140-6736(16)31134-5
  2. Zhou B., Perel P., Mensah G.A., Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat. Rev. Cardiol. 2021;published online May 28. https://doi.org/10.1038/s41569-021-00559-8
  3. Mills K.T., Stefanescu A., He J. The global epidemiology of hypertension. Nat. Rev. Nephrol 2020;16:223-37. https://doi.org/10.1038/s41581-019-0244-2
  4. Будневский А.В., Дробышева Е.С., Токмачев Р.Е., Резова Н.В. Влияние нарушения сна на течение артериальной гипертензии. Лечащий врач. 2019;7:28-30.
  5. NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. (published online Aug 24.). https://doi.org/10.1016/S0140-6736(21)01330-1
  6. Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. Артериальная гипертония среди лиц 25-64лет:распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4-14.
  7. Robillard R.P., Lanfranchi P.A., Prince F., et al. Sleep deprivation increases blood pressure in healthy normotensive elderly and attenuates the blood pressure response to orthostatic challenge. Sleep. 2011;34(3):335-39.
  8. Jonas M., Garfinkel D., Zisapel N., et al. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press. 2013;12(1):19-24.
  9. Фильченко И.А., Коростовцева Л.С., Терещенко Н.М. и др. Коморбидные инсомния и артериальная гипертензия: патогенетические модели и перспективные биомаркеры. Артериальная гипертензия. 2019;25(2):143-57 doi: 10.18705/1607-419X-2019-25-2-143-157
  10. Баланова Ю.А., Концевая А.В., Шальнова С.А. и др. Качество жизни лиц с артериальной гипертензией в россии - есть ли связь со статусом лечения (по данным популяционного исследования эссе-рф). Российский кардиологический журнал. 2016;(9):7-13
  11. Wang R., Zhaoa X., He X., et al. Impact of hypertension on health-related quality of life in a population-based study in Shanghai, China. Public Health. 2009;123(8):534-39.
  12. Tahkola A., Korhonen P., Kautiainen H., et al. The impact of antihypertensive treatment initiation on health-related quality of life and cardiovascular risk factor levels: a prospective, interventional study. BMC. Cardiovasc. Disord. 2021;21:444. https://doi.org/10.1186/s12872-021-02252-7
  13. Антипова Е.И., Шибкова Д.З. Оценка качества жизни специалистов по социальной работе с помощью опросника SF-36. Гигиена и санитария. 2016;95(4):369-75. https://doi.org/10.18821/0016-9900-2016-95-4-369-375
  14. Brazier J. Measuring and valuing health benefits for economic evaluation. Pharmacoeconomics. Oxford University Press. 2007;25(4):353.
  15. Schipper H., Clinch, J.J., Olweny C.L. Quality of life studies: definitions and conceptual issues, In Spilker B Quality of Life and Pharmacoeconomics in Clinical Trials. Lippincott-Raven Publishers: Philadelphia. 1996. P. 11-23.
  16. Казакова И.А., Ивлев Е.Н. Исследование качества жизни и выраженности депрессии у больных артериальной гипертензией, получающих лечение программным гемодиализом. Международный журнал сердца и сосудистых заболеваний. 2017;5(14):19-28.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies